Open Access
ARTICLE
STIL enhances the development of lung adenocarcinoma by regulating the glycolysis pathway
1 Department of Respiratory Medicine, Jen Ching Memorial Hospital, Suzhou, 215300, China
2 Department of Respiratory Medicine, Shandong Provincial Third Hospital, Jinan, 250010, China
* Corresponding Author: XIANJIN XIE. Email:
Oncology Research 2025, 33(1), 123-132. https://doi.org/10.32604/or.2024.048562
Received 12 December 2023; Accepted 19 April 2024; Issue published 20 December 2024
Abstract
Background: To investigate SCL/TAL 1 interrupting locus (STIL)’s role and prognostic significance in lung adenocarcinoma (LUAD) progression, we examined STIL and E2 promoter binding factor 1 (E2F1) expression and their impacts on LUAD prognosis using Gene Expression Profiling Interactive Analysis (GEPIA). Methods: Functional assays including CCK-8, wound-healing, 5-ethynyl-2-deoxyuridine (EdU), Transwell assays, and flow cytometry, elucidated STIL and E2F1’s effects on cell viability, proliferation, apoptosis, and migration. Gene set enrichment analysis (GSEA) identified potential pathways, while metabolic assays assessed glucose metabolism. Results: Our findings reveal that STIL and E2F1 are overexpressed in LUAD, correlating with adverse outcomes. It enhances cell proliferation, migration, and invasion, and suppresses apoptosis, activating downstream of E2F1. Silencing E2F1 reversed the promotion effect of the STIL overexpression on cell viability and invasiveness. Importantly, STIL modulates glycolysis, influencing glucose consumption, lactate production, and energy balance in LUAD cells. Conclusion: Our model, incorporating STIL, age, and disease stage, robustly predicts patient prognosis, underscored STIL’s pivotal role in LUAD pathogenesis through metabolic reprogramming. This comprehensive approach not only confirms STIL’s prognostic value but also highlights its potential as a therapeutic target in LUAD.Keywords
Supplementary Material
Supplementary Material FileCite This Article
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.